Axa’s Atara Biotherapeutics ATRA Stock Holding History

Axa’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-425	Closed	-$165K	–	1229
2021 Q2	$165K	Sell	425 -1,544	-78%	-$551K	﹤0.01%	1228
2021 Q1	$707K	Sell	1,969 -5,913	-75%	-$2.61M	﹤0.01%	1034
2020 Q4	$3.87M	Sell	7,882 -128	-2%	-$59.1K	0.01%	742
2020 Q3	$2.6M	Hold	8,010	–	–	0.01%	770
2020 Q2	$2.92M	Buy	8,010 +4,208	+111%	+$1.06M	0.01%	749
2020 Q1	$809K	Sell	3,802 -1,714	-31%	-$544K	﹤0.01%	888
2019 Q4	$2.27M	Buy	5,516 +4,727	+599%	+$1.63M	0.01%	786
2019 Q3	$279K	Buy	+789	New	+$294K	﹤0.01%	1195

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Axa's ATRA Position: Q3 2021 in Review

Axa sold out of Atara Biotherapeutics (ATRA) in Q3 2021, closing a stake of 425 shares — an estimated $165K sold.

Axa first reported a position in ATRA in Q3 2019 and held it in 8 quarters. The position peaked at $3.87M in Q4 2020. 140 funds tracked by Wall St. Rank hold ATRA as of Q3 2021.

Axa reported no remaining Atara Biotherapeutics position as of Q3 2021 after selling out during the quarter.
Axa sold 425 Atara Biotherapeutics shares in Q3 2021, an estimated $165K.
Axa first reported a position in Atara Biotherapeutics in Q3 2019 and held it in 8 quarters.
Axa's Atara Biotherapeutics position peaked at $3.87M in Q4 2020.
140 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2021.

Based on Axa's 13F filing for Q3 2021, filed 15 Nov 2021.